Monday, October 17, 2016 10:44:55 AM
Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that it has been notified by its Italian partner, Costruzione Strumenti Oftalmici (CSO), that all necessary documents have been completed and submitted to the United States Food and Drug Administration (FDA) for the Retimax™, also known as the Paramax. Paradigm is the exclusive representative for this significant new product in the U.S. market. "This new innovative device offers the earliest detection of glaucoma currently available and will be an excellent addition to Paradigm's glaucoma diagnostic products," said Stephen Davis, Paradigm's President and Chief Executive Officer.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM